Innate Pharma S.A. (LON: 0EVI)

London flag London · Delayed Price · Currency is GBP · Price in EUR
1.775
+0.029 (1.66%)
At close: Jan 22, 2025
-27.85%
Market Cap 123.61M
Revenue (ttm) 28.65M
Net Income (ttm) -28.87M
Shares Out n/a
EPS (ttm) -0.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 153
Average Volume 2,079
Open 1.749
Previous Close 1.746
Day's Range 1.732 - 1.775
52-Week Range 1.149 - 2.307
Beta 0.87
RSI 48.98
Earnings Date Mar 27, 2025

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head an... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 179
Stock Exchange London Stock Exchange
Ticker Symbol 0EVI
Full Company Profile

Financial Performance

In 2023, Innate Pharma's revenue was 61.64 million, an increase of 6.88% compared to the previous year's 57.67 million. Losses were -7.57 million, -86.97% less than in 2022.

Financial numbers in EUR Financial Statements

News

There is no news available yet.